G1 Therapeutics

G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.

Earnings data Q3 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1's Communications Officer Will Roberts will provide a corporate presentation on September 12, 2023, at 9:30 AM EDT during the H.C. Wainwright 25th Annual Global Investment Conference.

G1 Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

RESEARCH TRIANGLE PARK, N.C., Sept. 01, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 6,800 shares of G1's common stock and 3,300 restricted stock units (RSUs) to two hired employees under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan (the “Amended and Restated 2021 Plan”). These equity awards were granted as an inducement material to the new employee becoming an employee of G1 in accordance with Nasdaq Listing Rule 5635(c)(4).

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

G1 Therapeutics, Inc. (NASDAQ:GTHX ) Q2 2023 Earnings Conference Call August 2, 2023 8:30 AM ET Company Participants William Roberts - VP, IR & Corporate Communications John Bailey - CEO, President & Director Andrew Perry - Chief Commercial Officer Rajesh Malik - Chief Medical Officer John Umstead - CFO Conference Call Participants Gil Blum - Needham & Company Kaveri Pohlman - BTIG Anupam Rama - JPMorgan Chase & Co. Troy Langford - TD Cowen Operator Good day, and thank you for standing by. Welcome to the G1 Second Quarter Financial Results Conference Call.

G1 Therapeutics, Inc. (GTHX) Q2 2023 Earnings Call Transcript

G1 Therapeutics (GTHX) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of a loss of $0.17 per share. This compares to loss of $0.92 per share a year ago.

G1 Therapeutics (GTHX) Tops Q2 Earnings and Revenue Estimates

- Recognized Total Revenue of $42.4 Million, Including $11.1 Million in Net COSELA® (trilaciclib) Revenue - - Reiterated Expectation for Interim Overall Survival (OS) Analysis of Pivotal Phase 3 Trial in Metastatic Triple Negative Breast Cancer (TNBC) in the First Quarter of 2024 - - Presented New Phase 2 Results Confirming Benefit of Trilaciclib in Reducing Adverse Events Associated with an Antibody-Drug Conjugate (ADC) in Triple Negative Breast Cancer (TNBC) - - Provided Phase 2 Mechanism of Action Trial Results Clarifying Trilaciclib's Role in Enhancing Immune Surveillance and Efficacy as Measured by Long Term Endpoints like Overall Survival (OS) - - Improved Financial Strength By Amending Hercules Debt Facility and Receiving Payment from Simcere for Relief of Future Royalties; Cash Runway Extends Beyond Expected Clinical Trial Readouts in Early 2024 - - Management to Host Webcast and Conference Call today at 8:30 AM ET - RESEARCH TRIANGLE PARK, N.C., Aug. 02, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today provided a corporate and financial update for the second quarter ended June 30, 2023.

G1 Therapeutics Provides Second Quarter 2023 Financial Results and Operational Highlights

RESEARCH TRIANGLE PARK, N.C., July 31, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that it will participate in two August investor conferences.

G1 Therapeutics to Participate in Two August Investor Conferences

- Results Confirm that Trilaciclib Reduces Single and Multilineage Grade ≥3 Myelosuppressive Hematologic Adverse Events (HAEs) Including Neutropenia, Anemia, and Thrombocytopenia -

New Publication Highlights Real World Impact of Trilaciclib on Myelosuppressive Events in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)

RESEARCH TRIANGLE PARK, N.C., July 26, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a financial and corporate update for the second quarter 2023 on Wednesday August 2, 2023, at 8:30 a.m. ET.

G1 Therapeutics to Release Second Quarter 2023 Financial Results and Provide Business Update on August 2, 2023

Day One Biopharmaceuticals

Evaxion Biotech A/S

ImmunoGen

Shares of several cancer drug firms surged on Monday after the companies reported positive clinical trial data from their therapies at an ongoing industry conference in Chicago.

Cancer drugmakers rise as industry meet fuels investor interest

- Phase 2 Mechanism of Action Trial Results Demonstrate the Immunomodulatory Effects of Trilaciclib in the Tumor Microenvironment -

Trilaciclib Increases Pool of Memory T Cells in the Tumor Microenvironment Responsible for Long Term Immune Surveillance and Efficacy

The Company Also Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) in Conjunction with the Appointment The Company Also Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) in Conjunction with the Appointment

G1 Therapeutics Announces Appointment of Monica Thomas as General Counsel

GTHX halted the CRC trial on low survival benefits. There are reasons its other trials with trilaciclib could be more positive.

G1 Therapeutics: Without Cash, The CRC Failure Becomes A Tougher Hurdle

Real-World Data Show No Association Between Patient Characteristics and Risk of Myelosuppressive Events Real-World Data Show No Association Between Patient Characteristics and Risk of Myelosuppressive Events

New Study Confirms Consistent Risk of Myelosuppression Across All Patients Receiving Chemotherapy for Small Cell Lung Cancer

- On-Target Effect of Trilaciclib Reduces Rates of Multiple Adverse Events Associated with Sacituzumab Govitecan-Hziy by Over 50% Including Neutropenia, Anemia, and Diarrhea -

New Results from Phase 2 Trial Confirm Benefit of Trilaciclib in Reducing Adverse Events Related to an Antibody Drug Conjugate (ADC)

G1 Therapeutics, Inc. (NASDAQ:GTHX ) Q1 2023 Earnings Conference Call May 3, 2023 8:30 AM ET Company Participants Will Roberts - Investor Relations Jack Bailey - Chief Executive Officer Andrew Perry - Chief Commercial Officer Raj Malik - Chief Medical Officer John Umstead - Chief Financial Officer Conference Call Participants Gil Blum - Needham & Company Ed White - H.C. Wainwright Dane Leone - Raymond James Troy Langford - TD Cowen David Nierengarten - Wedbush Securities Kaveri Pohlman - BTIG Operator Good day and thank you for standing by.

G1 Therapeutics, Inc. (GTHX) Q1 2023 Earnings Call Transcript

G1 Therapeutics (GTHX) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss of $1.15 per share a year ago.

G1 Therapeutics (GTHX) Reports Q1 Loss, Tops Revenue Estimates

- Drove 18% Quarterly Net Revenue Growth of COSELA® (trilaciclib) Over the Fourth Quarter of 2022; Grew Quarterly Vial Volume by 21% Over Prior Quarter -

G1 Therapeutics Provides First Quarter 2023 Financial Results and Operational Highlights

RESEARCH TRIANGLE PARK, N.C., April 26, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a financial and corporate update for the first quarter 2023 on Wednesday May 3, 2023, at 8:30 a.m. ET.

G1 Therapeutics to Release First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023

G1 Therapeutics (GTHX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

G1 Therapeutics (GTHX) Moves to Buy: Rationale Behind the Upgrade

RESEARCH TRIANGLE PARK, N.C., April 11, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1's Chief Executive Officer Jack Bailey and other members of the Executive Team will participate in a fireside chat during the 22nd Annual Needham Virtual Healthcare Conference. The fireside chat will take place on Tuesday April 18th at 1:30 PM EDT.

G1 Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare Conference

Despite the recent debacle that clobbered this stock, G1 Therapeutics, Inc. could deliver you more upsides, as it'll likely make a comeback in H2 this year with more data releases. The Phase 3 (PRESERVE 1) trial for colorectal cancer cleared its primary endpoints. Nonetheless, the efficacy data was subpar, which renders further Cosela development for this particular cancer.

G1 Therapeutics: Unexpected Setbacks Yet Value Remains

G1 Therapeutics Inc. (NASDAQ:GTHX ) Q4 2022 Earnings Conference Call March 1, 2023 8:30 AM ET Company Participants Jack Bailey - Chief Executive Officer Jennifer Moses - Chief Financial Officer Raj Malik - Chief Medical Officer Andrew Perry - Chief Commercial Officer Will Roberts - Vice President, Communications Conference Call Participants Gil Blum - Needham & Co. Joseph Thome - Cowen & Co. Dane Leone - Raymond James Priyanka Grover - JP Morgan Operator Good day and welcome to the G1 Therapeutics fourth quarter financial results conference call. At this time, all participants are in a listen-only mode.

G1 Therapeutics (GTHX) Q4 2022 Earnings Call Transcript

G1 Therapeutics (GTHX) delivered earnings and revenue surprises of 14.12% and 6.64%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

G1 Therapeutics (GTHX) Reports Q4 Loss, Tops Revenue Estimates

- Achieved $31.3 Million in Net Revenue from Sales of COSELA® (trilaciclib) for Full Year 2022, Representing 182% Growth Over 2021; Provided 2023 Net COSELA Revenue Guidance of $50 to $60 Million -

G1 Therapeutics Provides Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights

RESEARCH TRIANGLE PARK, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that on March 7th, 2023, at 10:30 AM EST, G1's Chief Executive Officer Jack Bailey will participate in the moderated Breast and Lung Cancer Panel during the Cowen 43rd Annual Health Care Conference.

News for G1 Therapeutics Stock (GTHX)